Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2014, Article ID 307202, 5 pages
http://dx.doi.org/10.1155/2014/307202
Clinical Study

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

1University of Social Welfare and Rehabilitation Sciences (USWR), Razi Psychiatric Hospital, P.O. Box 18735-569, Tehran, Iran
2Razi Psychiatric Hospital, P.O. Box 18735-569, Tehran, Iran

Received 3 June 2014; Revised 14 August 2014; Accepted 15 August 2014; Published 26 August 2014

Academic Editor: Robin Emsley

Copyright © 2014 Saeed Shoja Shafti and Mahsa Gilanipoor. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone ( in each group) in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S), Schedule for Assessment of Insight (SAI), and finally Simpson Angus Scale (SAS) as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (), as regards negative symptoms, it was so only by means of olanzapine (). CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (). Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.